Synthaverse S.A.
SVE.WA
Warsaw Stock Exchange2.87
PLN
+0.02
- -
Synthaverse S.A.
SVE.WA
(Warsaw Stock Exchange)
Recent
price
2.87
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Synthaverse S.A. is a Poland-based global pharmaceutical company specializing in the production and sale of medicinal preparations, medical devices, and laboratory reagents. Founded in 1944 and headquartered in Lublin, Synthaverse operates primarily in the biotechnology and pharmaceutical sectors with a strong focus on immunotherapy. Its core product portfolio includes oncological immunotherapy drugs, notably the Onko BCG vaccine for bladder cancer, immunotherapies for serological conflict such as Gamma Anty-D, passive immunotherapy products for hepatitis B like Gamma Anty HBs, as well as probiotics including Lakcid, and other biologic medicines like Biotrombina, Gastrotrombina, Distreptaza, and Histaglobulina. The company manufactures injection drugs, lyophilized active substances in sterile sealed vials, drugs based on surface and submerged biological cultures, and suppository forms. Synthaverse distributes its products to around 50 countries worldwide, serving diverse markets including oncology, gynecology, proctology, and infectious diseases. In recent years, Synthaverse has undergone significant strategic transformation including a rebranding from Biomed Lublin Wytwornia Surowic i Szczepionek S.A. to Synthaverse S.A. in 2023, aiming to position itself as a global leader in life sciences. The company has invested heavily in innovation, notably commissioning a new Biotechnology Innovation Center with a commercial production line for Onko BCG, although the product launch has been postponed to 2027 to allow for expanded production capacity and market registration processes. Synthaverse maintains compliance with Good Manufacturing Practice (GMP) standards and pharmacovigilance requirements to ensure high-quality and safe medicinal products. Its strategic shifts include increased production volumes, ongoing development of new immunotherapeutic drugs, and expanding partnerships within scientific centers globally to enhance R&D capabilities. Synthaverse’s latest focus involves ramping up production series sizes and broadening its market footprint despite recent declines in state contracts for vaccines. The company’s strategic emphasis on immunotherapy and biologic medicines in oncology and other therapeutic areas combined with its contract manufacturing services for medicinal products, medical devices, and reagents position it as a specialized player in pharmaceutical innovation and production. Synthaverse employs advanced technologies and invests in scientific research collaboration and health knowledge to develop unique and effective solutions shaping global health. The company’s business operations span Poland primarily, with growing outreach across European and international markets. Its workforce comprises over 200 employees supporting a broad product pipeline and service offerings tailored for both public healthcare systems and private sector clients worldwide. Synthaverse's key recent corporate changes include the 2023 corporate name change, the establishment of a new production plant for Onko BCG, and a revised product launch timeline aimed at solidifying its position in oncological immunotherapy. The company continues to expand its commercial capabilities and strengthen operational execution within the biotechnology and pharmaceutical industry. Its ongoing innovation and regulatory compliance underscore a commitment to high-quality medicinal solutions across its core therapy areas.